Podcast
BioCentury This Week
Hosted by BioCentury · EN
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
35episodes
Episodes
Newest firstAll episodes
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
3d ago00:42:07Tap to summarizeThe departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what Vallance’s exit, the appointment of John Healey as Chancellor of the Exchequer and other changes arriving with the new Prime Minister could mean for life sciences in the country. BioCentury’s analysts also discuss an ambitious U.K. data initiative launched this month. The Health Data Research Service is intended to be a single front door to all NHS health records, offering large-scale longitudinal health data across diverse populations.Beyond the U.K., the team turns to companies to watch in Taiwan, what’s next for Biogen’s anti-tau therapy, Eli Lilly’s proposed acquisition of psychedelics company AtaiBeckley, and the latest changes at FDA. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660194#Biotech #LifeSciences #UKBiotech #HealthData #FDA00:01 - Sponsor Message: CBRE02:23 - U.K. Leadership Changes09:21 - U.K. Data Initiative10:52 - Taiwan Biotech16:44 - Biogen’s Tau Data27:18 - Lilly’s Psychedelics Takeout28:20 - FDATo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
1w ago00:29:16Tap to summarizeAfter nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding beyond the sector’s traditional hubs. On a special episode of the BioCentury This Week podcast, Ian Anderson, senior director, head of U.S. life sciences & healthcare research at CBRE, joins BioCentury’s analysts to discuss the company’s recent report on life sciences talent trends, and how those trends are driving property demand. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660118#LifeSciences #BiotechJobs #Workforce #LifeSciencesRealEstate #Talent00:01 - Sponsor Message: CBRE00:45 - Industry Inflection Point04:17 - Report Methodology10:08 - Growth Beyond Big Hubs15:28 - Capital Markets Signals18:48 - AI and Space Use20:50 - Emerging Talent26:34 - Up-and-Coming CitiesTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 376 - M&A momentum: 3Q public markets preview
1w ago00:33:01Tap to summarizeM&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public Markets Preview, asking whether M&A momentum can carry biotech through year-end and what happens if the AI trade goes bust?Editor in Chief Simone Fishburn gives her perspective on what incoming Prime Minister Andy Burnham’s agenda means for U.K. life sciences. The analysts also discuss Ionis’ ATTR-CM miss and Takeda’s orexin program. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660118#BiotechMA #BiotechInvesting #PublicMarkets #LifeSciences #DrugDevelopment00:01 - Sponsor Message: CBRE01:46 - 3Q Market Preview10:54 - Burnham’s Britain19:40 - Ionis' ATTR-CM Miss29:12 - Takeda Orexin ProgramTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
2w ago00:33:44Tap to summarizeNovartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how the deal fits with the Swiss pharma’s cancer toolkit.The analysts then discuss MHRA CEO Lawrence Tallon’s Guest Commentary in BioCentury on making regulation a catalyst for U.K. life sciences and why the primary defeat of Rep. Diana DeGette (D-Colo.) is a setback for FDA reforms. They also assess how single-cell Parkinson’s atlases reveal neuronal and glial disruptions in specific regions and stages, and the thin evidence underpinning Congress’ probe of China trial consent. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660033#ADC #BiotechMA #ParkinsonsDisease #FDA #ChinaBiotech00:01 - Sponsor Message: CBRE01:15 - Novartis Buying Myricx08:01 - U.K. Regulation14:44 - DeGette & FDA Reform21:51 - Parkinson's Atlas Insights29:39 - China Trials ProbeTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 374 - Parkinson's deep dive & FDA trial reforms
3w ago00:34:14Tap to summarizeNew Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts review the most promising targets and trends shaping the Parkinson’s treatment landscape.The team then turns to AstraZeneca’s build-out of its obesity portfolio, followed by FDA’s Operation TrialBlazer and what the reforms mean for reducing the time to launch a clinical trial in the U.S. — and whether they can help close the gap with China.Finally, the analysts review recent FDA reversals of controversial regulatory decisions made under former Commissioner Marty Makary’s leadership and whether companies and investors can expect this reversion to the mean to carry forward.View full story: https://www.biocentury.com/article/659958#ParkinsonsDisease #ObesityDrugDevelopment #FDA #ClinicalTrials #DrugDevelopment00:00 - Introduction01:40 - Parkinson's New Targets11:43 - AstraZeneca's Obesity Pipeline18:37 - FDA's Operation TrialBlazer27:33 - FDA Leadership OutlookTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
Jun 2300:30:10Tap to summarizeAbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeout and the assets AbbVie gains.The analysts then discuss moves by FDA to reverse controversial setbacks that occurred under the agency’s former leadership and assess Acting CDER Director Michael Davis’ memo outlining how his predecessor repeatedly overruled career staff to quash a drug approval. The analysts also discuss continuing signs of political involvement at FDA.Finally, they discuss China NMPA’s first-ever approval of a CAR T for solid tumors, satricabtagene autoleucel (satri-cel) from Carsgen.View full story: https://www.biocentury.com/article/659864#BiotechMA #Immunology #FDA #CART #ChinaBiotech00:59 - AbbVie Buys Apogee05:20 - uniQure U-turn09:02 - FDA Reversals12:32 - Tzield Memo20:53 - Solid Tumor CAR T ApprovalTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
Jun 1600:25:13Tap to summarizeBiotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $770 million debut by Parabilis, the largest IPO in the sector’s history.The analysts also discuss the Biosecure Act and U.S. policy toward China; the cachexia pipeline; and BioCentury’s updated Innovation Distillery.View full story: https://www.biocentury.com/article/659773 #BiotechIPO #NASDAQ #BiosecureAct #Cachexia #ChinaBiotech 00:36 - Innovation Distillery03:56 - Biotech IPOs10:13 - Biosecure Act, WuXi AppTec16:03 - Cachexia Pipeline22:03 - Ouster for RFK Jr.?To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 371 - Moving faster at the academia-industry interface
Jun 1100:32:43Tap to summarizeGetting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Rounds-U.S. conference brought together academic innovators, biopharma leaders and early-stage investors to debate key bottlenecks in translation and how to make early-stage R&D investible.Sam Blackman, entrepreneur in residence at GV and co-founder of Day One Biopharmaceuticals, and Aaron Coe, managing director of innovation for the Allen Institute, joined BioCentury’s analysts on stage last week in Seattle for a podcast recording to wrap up Grand Rounds and discuss key takeaways from the event.Editor’s note: We invite you to join BioCentury and Regional Host Chairs Forbion and BGV at our next edition of BioCentury Grand Rounds, scheduled for Sept. 23-25 in Amsterdam.View full story: https://www.biocentury.com/article/659729#TranslationalScience #DrugDevelopment #BiopharmaInnovation #AcademicInnovation #GrandRoundsUS00:53 - World-Class Regional Hosts02:56 - Building Grand Rounds Community05:21 - Two Nobels, One City07:43 - AI Goes End-to-End09:47 - The Data Problem14:12 - AI, Animals, Australia19:53 - Study Startup Bottlenecks26:11 - Early Science InvestabilityTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
Jun 900:34:57Tap to summarizeFDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses how FDA’s new, interim leaders have changed the tone at the agency and why they are putting medicines derailed under former FDA Commissioner Marty Makary back on track. Usdin also highlights FDA’s new real-time clinical trials initiative.BioCentury’s analysts then turn to deals, including an analysis of the 20 deals Eli Lilly has done this year; Servier’s move to expand in neurology via BD; and Monday’s billion-dollar deals by Incyte, which will acquire Vega Therapeutics, and Johnson & Johnson, which is buying Firefly Bio.The team also discusses Grand Rounds U.S., held last week in Seattle, including the conference’s Rising Star prize winner Sylvain Simon of Fred Hutchinson Cancer Center.View full story: https://www.biocentury.com/article/659699#FDA #BiopharmaDeals #ClinicalTrials #BiotechMA #GrandRoundsUS01:23 - Grand Rounds Seattle Takeaways04:43 - FDA's New Leaders11:48 - FDA's Real Time Trials Pilot20:40 - Servier Bets on Neuro25:33 - Lilly's Deal Spree30:21 - Dealmaking RoundupTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Jun 200:39:13Tap to summarizeRevolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data for the company’s daraxonrasib, Akeso’s Harmoni-6 readout, as well as other results from the meeting. BioCentury’s analysts then argue that U.S. biotech executives and policymakers should embrace the challenges and opportunities that come with the rise of innovation in China — rather than sticking their heads in the sand. They also discuss why leaders of the U.S.’s biggest drug companies should use their influence to stop an OMB proposal that threatens the foundations of U.S. science. Plus: takeaways from BioCentury's conversation with Alkermes CEO Richard Pops on The BioCentury Show.View full story: https://www.biocentury.com/article/659629#ASCO #PancreaticCancer #BiotechInnovation #ChinaBiotech #DrugDevelopment00:00 - Introduction01:49 - ASCO: RevMed06:50 - ASCO: Akeso16:33 - China U.S. Biotech Rivalry24:15 - Science Under Threat36:29 - Richard Pops TakeawaysTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →